$3.65 Billion is the total value of Rock Springs Capital Management LP's 143 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BAX | BAXTER INTL INC | $55,535,000 | +6.0% | 645,000 | 0.0% | 1.52% | -29.7% | |
| SRPT | SAREPTA THERAPEUTICS INC | $55,397,000 | +63.9% | 345,500 | 0.0% | 1.52% | +8.7% | |
| BIIB | BIOGEN INC | $48,159,000 | -15.4% | 180,000 | 0.0% | 1.32% | -43.9% | |
| TFX | TELEFLEX INCORPORATED | $47,317,000 | +24.3% | 130,000 | 0.0% | 1.30% | -17.5% | |
| IDXX | IDEXX LABS INC | $41,270,000 | +36.3% | 125,000 | 0.0% | 1.13% | -9.6% | |
| BSX | BOSTON SCIENTIFIC CORP | $38,621,000 | +7.6% | 1,100,000 | 0.0% | 1.06% | -28.6% | |
| EXAS | EXACT SCIENCES CORP | $36,863,000 | +49.9% | 424,000 | 0.0% | 1.01% | -0.6% | |
| VRTX | VERTEX PHARMACEUTICALS INC | $36,289,000 | +22.0% | 125,000 | 0.0% | 1.00% | -19.1% | |
| GLPG | GALAPAGOS NVspon adr | $34,526,000 | +0.7% | 175,000 | 0.0% | 0.95% | -33.2% | |
| AMRN | AMARIN CORP PLCspons adr new | $32,178,000 | +73.0% | 4,650,000 | 0.0% | 0.88% | +14.8% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $31,577,000 | +31.3% | 213,500 | 0.0% | 0.87% | -12.9% | |
| AMGN | AMGEN INC | $29,718,000 | +16.3% | 126,000 | 0.0% | 0.82% | -22.8% | |
| INCY | INCYTE CORP | $25,993,000 | +42.0% | 250,000 | 0.0% | 0.71% | -5.8% | |
| ACHC | ACADIA HEALTHCARE COMPANY IN | $22,608,000 | +36.9% | 900,000 | 0.0% | 0.62% | -9.2% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $20,563,000 | +7.2% | 1,175,000 | 0.0% | 0.56% | -28.9% | |
| CYTOKINETICS INCnote 4.000%11/1 | $19,082,000 | +80.5% | 8,000,000 | 0.0% | 0.52% | +19.7% | ||
| WST | WEST PHARMACEUTICAL SVSC INC | $16,129,000 | +49.2% | 71,000 | 0.0% | 0.44% | -1.1% | |
| GH | GUARDANT HEALTH INC | $15,415,000 | +16.6% | 190,000 | 0.0% | 0.42% | -22.7% | |
| JNJ | JOHNSON & JOHNSON | $14,766,000 | +7.2% | 105,000 | 0.0% | 0.40% | -28.8% | |
| MNTA | MOMENTA PHARMACEUTICALS INC | $13,308,000 | +22.3% | 400,000 | 0.0% | 0.36% | -18.9% | |
| CNMD | CONMED CORP | $12,958,000 | +25.7% | 180,000 | 0.0% | 0.36% | -16.7% | |
| HCAT | HEALTH CATALYST INC | $12,397,000 | +11.5% | 425,000 | 0.0% | 0.34% | -26.1% | |
| NVCR | NOVOCURE LTD | $10,378,000 | -11.9% | 175,000 | 0.0% | 0.28% | -41.5% | |
| XENT | INTERSECT ENT INC | $6,770,000 | +14.3% | 500,000 | 0.0% | 0.19% | -24.1% | |
| TXG | 10X GENOMICS INC | $6,788,000 | +43.3% | 76,000 | 0.0% | 0.19% | -5.1% | |
| INSMED INCnote 1.750% 1/1 | $5,861,000 | +16.3% | 6,000,000 | 0.0% | 0.16% | -22.6% | ||
| CO | GLOBAL CORD BLOOD CORPORATIO | $2,868,000 | -2.5% | 925,000 | 0.0% | 0.08% | -35.2% | |
| RETROPHIN INCnote 2.500% 9/1 | $2,713,000 | +5.7% | 3,250,000 | 0.0% | 0.07% | -30.2% | ||
| NEUROCRINE BIOSCIENCES INCnote 2.250% 5/1 | $1,673,000 | +30.0% | 1,000,000 | 0.0% | 0.05% | -13.2% | ||
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,460,000 | +0.8% | 1,500,000 | 0.0% | 0.04% | -33.3% | ||
| RADIUS HEALTH INCnote 3.000% 9/0 | $1,105,000 | +3.6% | 1,500,000 | 0.0% | 0.03% | -31.8% | ||
| PACIRA BIOSCIENCESnote 2.375% 4/0 | $1,094,000 | +13.3% | 1,000,000 | 0.0% | 0.03% | -25.0% | ||
| BMYRT | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $663,000 | -5.8% | 185,150 | 0.0% | 0.02% | -37.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.